Sybron Dental Specialties, Inc. Reports 17.0% Increase in Net Sales for Fourth Quarter of Fiscal 2005

NEWPORT BEACH, Calif., Dec. 12  /PRNewswire-FirstCall/ -- Sybron Dental Specialties, Inc. (NYSE:SYD), a leading manufacturer of a broad range of value-added products for the dental profession, including the specialty markets of orthodontics, endodontics and implantology, announced today its financial results for its fourth fiscal quarter and fiscal year ended September 30, 2005.

  (Logo:  http://www.newscom.com/cgi-bin/prnh/20001204/SDSLOGO )

  FOURTH QUARTER RESULTS


Net sales for the fourth quarter of fiscal 2005 totaled $170.4 million, an increase of 17.0% over the $145.7 million in net sales in the corresponding prior year period.  Sybron's internal net sales, which exclude currency fluctuations and include only the organic growth of acquisitions made in the past twelve months, grew 11.8% in the fourth quarter over the same period of the prior year.  The internal net sales growth rate of the Company's consumable products was 11.7%.  The sales of these products accounted for approximately 97% of the Company's total net sales in the quarter.

Net income for the fourth quarter of fiscal 2005 was $21.5 million, an increase of 33.5% over net income of $16.1 million in the same period of the prior year.  Fully diluted earnings per share were $0.52 in the fourth quarter of fiscal 2005, an increase of 30.0% over fully diluted earnings per share of $0.40 in the same period of the previous year.  Net income and earnings per share in the fourth quarter of fiscal 2005 were positively impacted by the adjustment of the annual effective tax rate, as well as adjustments of certain tax liabilities.

In the fourth quarter of fiscal 2005, Sybron generated $31.0 million in free cash flow, defined as cash flows from operating activities of $38.3 million minus capital expenditures of $7.3 million.  This compares with free cash flow of $19.5 million in the fourth quarter of fiscal 2004 (cash flows from operating activities of $25.0 million minus capital expenditures of $5.5 million).

"A strong new product pipeline, outstanding efforts by our sales force and the continuing adoption of our Damon self-ligating system helped drive the highest level of internal net sales growth in two years," said Floyd W. Pickrell, Jr., Chief Executive Officer of Sybron Dental Specialties.  "We are also extremely pleased with our improvement in working capital management, as both our inventory days and days sales outstanding reached record low levels in the fourth quarter.  Our continued sales momentum and improved working capital management are helping to drive strong returns on capital and creating additional value for our shareholders."

"Sales were strong across the Company and we executed well in all areas except for expense control, which will receive additional focus in fiscal 2006," said Mr. Pickrell.

SEGMENT SALES HIGHLIGHTS

In the fourth quarter, internal net sales of the Company's Professional Dental segment increased 12.9% over the same period in the prior year. Internal net sales of Professional Dental consumable products increased 12.4%. Net sales in the quarter were positively impacted by continued strong sales of MaxCem self-adhesive cement, double-digit sales growth in the infection prevention line of products, as well as the launch of the new Demetron LED II curing light.

During the fourth quarter, internal net sales of the Company's Specialty Products segment grew 10.6% over the same period in the prior year.  Total net sales were positively impacted by the launch of the metal version of the Damon 3 self-ligating bracket, increasing sales of the Damon brackets in international markets and continued double-digit sales growth in the endodontics line of products.

FOURTH QUARTER FINANCIAL HIGHLIGHTS

Gross margins in the fourth quarter of 2005 were 55.3%, compared with 54.8% in the same period of the prior year.  The improvement in gross margin was primarily attributable to the Company's increased sales of higher gross margin products such as dental implants.  This improvement was partially offset by costs related to the closure of the Company's Demetron manufacturing facility.

Selling, general and administrative expenses (SG&A) were $63.2 million, or 37.1% of net sales, in the fourth quarter of 2005, compared with $51.0 million, or 35.0% of net sales, in the same period of the prior year.  A non-cash charge of $2.0 million was recorded as a result of impairment to several intangible assets.  The largest asset, which related to intellectual property associated with disinfecting solutions, became impaired throughout fiscal 2001 and fiscal 2002, at which time the charges should have been taken. The Company's management concluded that the effect of the delay in recording the charges was not material to any of the prior periods in which impairment occurred and the correcting entries are not material to the fourth quarter of fiscal 2005.  Higher incentive compensation and Sarbanes-Oxley compliance costs also contributed to the increase in SG&A.

Research and development expenditures were $3.5 million in the fourth quarter of fiscal 2005, an increase of 20.7% over $2.9 million of expenditures in the same period of the prior year.

Operating income for the fourth quarter of fiscal 2005 was $31.0 million, compared to $28.9 million in the fourth quarter of fiscal 2004.  Earnings before interest, taxes, depreciation and amortization (EBITDA) for the quarter was $35.9 million, compared with EBITDA of $33.0 million in the fourth quarter of fiscal 2004.  Operating income was 18.2% and EBITDA was 21.1% of net sales for the quarter, compared with 19.8% and 22.7%, respectively, in the same period of 2004.  Fourth quarter 2005 EBITDA is calculated by adding net income of $21.5 million, income taxes of $4.7 million, net interest expense of $4.8 million, and depreciation and amortization of approximately $4.9 million. Fourth quarter 2004 EBITDA is calculated by adding net income of $16.1 million, income taxes of $7.9 million, net interest expense of $5.1 million and depreciation and amortization of approximately $3.9 million.

Sybron's effective tax rate in the fourth quarter of fiscal 2005 was 17.9%, compared with 33.0% in the fourth quarter of fiscal 2004.  The lower tax rate is attributable to both the revision of the annual rate as well as discrete adjustments.  The annual rate, excluding discrete adjustments, was determined to be 30.8% and, as a result, a credit of $1.0 million was recorded to adjust the 32% rate that had been used during the first nine months of the year.  The lower rate is attributable primarily to the decision not to repatriate funds from a non-US location.  Discrete adjustments related to the reversal and establishment of various tax liabilities, were also recorded during the quarter and netted to a $2.4 million positive impact.  The annual rate, excluding discrete adjustments is calculated by adding income taxes reported for fiscal 2005 of $28.4 million and discrete items of $4.0 million ($2.4 million of which were recorded in the fourth quarter of fiscal 2005) and then dividing this total by the Company's fiscal 2005 reported income before taxes of $105.1 million.  The effective income tax rate is expected to increase from 30.8% in fiscal 2005 to 33% in fiscal 2006, primarily as a result of lower expected foreign tax credit utilization in fiscal 2006 and an increase in the percentage of earnings coming from higher tax rate jurisdictions.

Net trade receivables were $112.5 million and days sales outstanding (DSOs) were 54.5 days at September 30, 2005, compared to 58.8 days at September 30, 2004.

Net inventory was $92.8 million at September 30, 2005 and inventory days were 118 days, compared to 133 days at September 30, 2004 and 121 days at June 30, 2005.

Please refer to the supplemental schedules, provided on the Financial Reports section of Sybron's Investor Relations web site (http://www.sybrondental.com/investors/index.html), for a detailed calculation of the Company's DSOs and inventory days.

Capital expenditures were $7.3 million in the fourth quarter of fiscal 2005, compared to $5.5 million in the same period of the previous year.

The average debt outstanding for the quarter was $222.5 million with an average interest rate of 7.8%.  The Company paid down $21.7 million in debt during the quarter, leaving total debt outstanding at September 30, 2005 of $211.8 million.

Sybron's cash and cash equivalents balance was $58.6 million at September 30, 2005, compared with $46.8 million at June 30, 2005.

Sybron's capital structure was 34.5% debt and 65.5% equity at September 30, 2005.  This compares with 42.5% debt and 57.5% equity at September 30, 2004.

  FULL YEAR 2005 FINANCIAL HIGHLIGHTS
  The following is a summary of the key financial highlights in fiscal 2005:

  *  Net sales totaled $649.7 million, compared to $574.0 million in fiscal
     2004, an increase of 13.2%.
  *  Net income was $76.7 million, compared to $62.1 million in fiscal 2004,
     an increase of 23.5%.
  *  Earnings per diluted share was $1.85, compared to $1.54 in fiscal 2004,
     an increase of 20.1%.
  *  Inventory days were reduced from 133 to 118.
  *  Free cash flow was $80.9 million, defined as cash flows from operating
     activities of $100.3 million minus capital expenditures of $19.4
     million.
  *  $8.8 million of debt was retired, two cash acquisitions totaling
     $69.9 million were completed and cash increased to $58.6 million from
     $40.6 million at September 30, 2004.

  OUTLOOK


For the first quarter of fiscal 2006, Sybron expects revenue to range from $160.0 million to $165.0 million, and diluted earnings per share to range from $0.35 to $0.40, which reflects the adoption of SFAS 123R, "Share-Based Payment."  On a pro forma basis, excluding tax-effected stock compensation expense, diluted earnings per share would range from $0.39 to $0.44.  For additional information, please see the attached reconciliation of pro forma and GAAP results.

For the full fiscal year 2006, Sybron expects revenue to range from $685.0 million to $705.0 million (with internal net sales growth between 6% and 9%).  The Company's revenue estimates for fiscal 2006 exclude the impact of potential acquisitions.  Sybron also expects diluted earnings per share for fiscal 2006 to range from $1.77 to $1.92 (which also reflects the adoption of SFAS 123R).  Based on current assumptions the Company expects to record $11.3 million in stock compensation expense ($7.6 million after tax) during fiscal 2006.  The impact of the adoption of SFAS 123R is based on the Company's current estimates and may differ materially from actual results due to changes in the number of options granted or the number of options forfeited.  On a pro forma basis, excluding tax-effected stock compensation expense, diluted earnings per share would range from $1.95 to $2.10.  For additional information, please see the attached reconciliation of pro forma and GAAP results.

In support of its outlook for fiscal 2006, the Company cited the following catalysts for the anticipated growth in revenue and earnings:

  *  Healthy end-user demand in its key markets;
  *  Continued roll-out of the Damon product line including the metal and
     aesthetic versions of the self-ligating bracket, as well as the self-
     ligating buccal tubes;
  *  Continued emphasis on manufacturing cost reductions; and
  *  Cost control measures for specific selling, general and administrative
     expenses



Commenting on the outlook for Sybron, Mr. Pickrell said, "We intend to continue our strategy of focusing our efforts on the fastest growing areas of dentistry.  Our productive R&D efforts and acquisitions have provided a broad portfolio of products to capitalize on high growth areas such as self-ligating appliances, dental implants, endodontics and all of the major dental resin categories.  Our balance sheet is also the strongest it has been since our spin-off, which provides us the financial flexibility to continue pursuing attractive acquisition opportunities.  Entering fiscal 2006, Sybron has never been in a stronger position, and we expect to continue delivering significant growth in revenue, earnings and cash flow over the long-term."

NON-GAAP FINANCIAL MEASURES

The Company has included information concerning EBITDA and free cash flow because management believes that certain investors use this information as measures of a company's performance and ability to service its debt.  EBITDA and free cash flow should not be considered as alternatives to, or more meaningful than, net income as an indicator of Sybron's operating performance or cash flows as a measure of liquidity.  EBITDA and free cash flow have not been prepared in accordance with generally accepted accounting principles (GAAP).  EBITDA and free cash flow, as presented by Sybron, may not be comparable to similarly titled measures reported by other companies.

The Company has included information concerning its annual tax rate, excluding discrete adjustments in fiscal 2005, because management believes that certain investors will use this information to understand the impact of discrete adjustments the Company made in the fourth quarter of fiscal 2005. Sybron's annual tax rate, excluding discrete adjustments has not been prepared in accordance with GAAP and should not be considered as an alternative to, or more meaningful than effective tax rate as an indicator of Sybron's tax expense as a percent of income before taxes.  Annual tax rate, excluding discrete adjustments, as presented by Sybron, may not be comparable to similarly titled measures reported by other companies.

The Company has included pro forma results for the fourth quarter of fiscal 2005, the full year of fiscal 2005, the first quarter of fiscal 2006 and the full year of fiscal 2006, as well as reconciliations of these pro forma results to reported earnings and earnings per share under GAAP because management believes that certain investors will use this information to understand the impact of the company's adoption of SFAS 123R, "Share-Based Payment".  Pro-forma net income and pro forma fully diluted earnings per share have not been prepared in accordance with GAAP.  Pro forma net income and pro forma fully diluted earnings per share should not be considered as alternatives to, or more meaningful than, net income or fully diluted earnings per share as indicators of Sybron's operating performance.  Pro forma net income and pro forma fully diluted earnings per share, as presented by Sybron, may not be comparable to similarly titled measures reported by other companies.

CONFERENCE CALL AND WEBCAST

The Company will host a conference call on Tuesday, December 13, 2005 at 9:00 a.m. Pacific Time to review the information in this press release and respond to questions.  The dial-in number for the call is [phone] for domestic callers and [phone] for international callers, passcode 802254.

A recorded replay of the conference call will be offered beginning at 12:30 p.m. Pacific Time on Tuesday, December 13th via both the Company's website and a telephone dial-in number.  The telephone dial-in number for the recorded replay is [phone], passcode 802254 for domestic callers and [phone], passcode 802254 for international callers.  The telephone replay will be available through 11:59 p.m. Pacific Time on December 16th, 2005.

The live webcast and archived replay may be accessed in the Investor Relations section of Sybron Dental's website at http://www.sybrondental.com/.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Statements made in this press release regarding future matters are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements, including those dealing with the Company's expectations as to its future revenue; earnings per share; organic growth, stock compensation expense; the demand for its products; the development, introduction and sales of new products; the increase in demand in orthodontics for self-ligating brackets; the Company's ability to capitalize on the demand for self-ligating brackets with its Damon brand of products and; the Company's ability to reduce its manufacturing, selling, general and administrative expenses are based on the Company's current expectations.  Our actual results may differ materially from those currently expected or desired because of a number of risks and uncertainties, including the level of demand for the Company's products; regulatory compliance; currency exchange rate fluctuations; distributor inventory adjustments; the intensity of competition; changes in the number of stock options granted or the number of options forfeited; and other factors affecting the Company's business prospects discussed in filings made by the Company, from time to time, with the SEC including the factors discussed in the "Cautionary Factors" section in Item 7 of the Company's most recent Annual Report on Form 10-K and its periodic reports on Form 10-Q.  We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

BUSINESS DESCRIPTION

Sybron Dental Specialties and its subsidiaries are leading manufacturers of both a broad range of value-added products for the dental profession, including the specialty markets of orthodontics, endodontics and implantology, and a variety of infection prevention products for use by the medical profession.

               SYBRON DENTAL SPECIALTIES, INC. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF INCOME
                   (in thousands, except per share amounts)
                                 (unaudited)

                                     Three Months Ended  Twelve Months Ended
                                       September 30,        September 30,
                                       2005      2004      2005      2004
  Net sales                          $170,396  $145,680  $649,666  $573,976
  Cost of sales
    Cost of products sold              75,667    65,921   284,035   256,191
    Restructuring charges                 512      (143)      588     1,471
      Total cost of sales              76,179    65,778   284,623   257,662
  Gross profit                         94,217    79,902   365,043   316,314
    Selling, general and
     administrative expenses           62,264    50,747   237,216   202,204
    Restructuring charges                 128        --       616      (488)
    Amortization of intangible
     assets                               789       294     2,579     1,232
      Total selling, general and
       administrative expenses         63,181    51,041   240,411   202,948
  Operating income                     31,036    28,861   124,632   113,366
  Other income (expense)
       Interest expense                (4,436)   (4,709)  (18,473)  (19,487)
       Amortization of deferred
        financing fees                   (408)     (415)   (1,653)   (1,625)
       Other, net                          41       331       585       451
  Income before income taxes           26,233    24,068   105,091    92,705
  Income taxes                          4,704     7,943    28,406    30,593
       Net income                     $21,529   $16,125   $76,685   $62,112

  Earnings per share:
       Basic earnings per share         $0.53     $0.41     $1.92     $1.61
       Diluted earnings per share       $0.52     $0.40     $1.85     $1.54

  Weighted average basic shares
   outstanding                         40,374    39,045    40,005    38,637
  Weighted average diluted shares
   outstanding                         41,730    40,584    41,451    40,253



              SYBRON DENTAL SPECIALTIES, INC. AND SUBSIDIARIES
                         CONSOLIDATED BALANCE SHEETS
                  (in thousands, except per share amounts)
                                 (unaudited)

                                               September 30,   September 30,
                                                   2005            2004
                                   ASSETS
  Current assets
       Cash and cash equivalents                  $58,572         $40,602
       Accounts receivable (less
        allowance for doubtful
        receivables of $3,007 and
        $2,094 at September 30, 2005
        and September 30, 2004,
        respectively)                             112,500         104,148
       Inventories                                 92,840          93,689
       Deferred income taxes                        7,788           3,293
       Prepaid expenses and other
        current assets                             12,261          12,975
                 Total current assets             283,961         254,707
  Property, plant and equipment, net of
   accumulated depreciation of $117,252
   and $101,934 at September 30, 2005
   and September 30, 2004, respectively            87,762          83,121
  Goodwill                                        295,306         268,768
  Intangible assets, net                           50,882          16,178
  Other assets                                     32,507          23,784
                 Total assets                    $750,418        $646,558



                    LIABILITIES AND STOCKHOLDERS' EQUITY
  Current liabilities
       Accounts payable                           $20,135         $19,512
       Current portion of long-term
        debt                                          733             882
       Income taxes payable                        11,822          17,089
       Accrued payroll and employee
        benefits                                   31,537          29,712
       Restructuring reserve                           --             711
       Accrued rebates                              9,336           9,475
       Accrued interest                             3,519           3,620
       Other current liabilities                   15,412          12,291
                 Total current
                  liabilities                      92,494          93,292
  Long-term debt                                   61,099          69,589
  Senior subordinated notes                       150,000         150,000
  Deferred income taxes                            16,405          12,266
  Other liabilities                                28,267          22,639
     Total liabilities                            348,265         347,786
  Commitments and contingent
   liabilities
  Stockholders' equity
            Preferred stock, $.01 par
             value; authorized 20,000
             shares, no shares
             outstanding                               --              --
            Common stock, $.01 par
             value; authorized 250,000
             shares, 40,395 and 39,307
             shares issued and
             outstanding at
             September 30, 2005 and
             September 30, 2004,
             respectively                             404             393
  Additional paid-in capital                      118,448          93,817
  Retained earnings                               264,841         188,156
  Accumulated other comprehensive income           18,460          16,406
                 Total stockholders' equity       402,153         298,772
                 Total liabilities and
                  stockholders' equity           $750,418        $646,558



              SYBRON DENTAL SPECIALTIES, INC. AND SUBSIDIARIES
                    CONSOLIDATED STATEMENTS OF CASH FLOWS
                               (in thousands)
                                 (unaudited)

                                           Twelve Months Ended September 30,
                                              2005                 2004
  Cash flows from operating activities:
       Net income                           $76,685              $62,112
       Adjustments to reconcile net
        income to net cash provided by
        operating activities:
          Depreciation                       15,060               13,361
          Loss on impairment of long-
           lived assets                       3,219                   --
          Amortization of intangible
           assets                             2,579                1,232
          Amortization of deferred
           financing fees                     1,653                1,625
          Loss (gain) on sales of
           property, plant and
           equipment                            374                 (253)
          Provision for losses on
           doubtful receivables                 775                  916
          Inventory provisions                4,401                4,406
       Deferred income taxes                  1,279                 (950)
       Tax benefit from issuance of
        stock under employee stock
        option plan                           7,794                4,749
       Changes in assets and
        liabilities, net of effects of
        businesses acquired:
          Increase in accounts
           receivable                        (5,446)                (356)
          (Increase) decrease in
           inventories                        6,992               (9,880)
          (Increase) decrease in
           prepaid expenses and other
           current assets                     1,250               (1,299)
          Decrease in accounts payable         (692)                (115)
          Increase (decrease) in income
           taxes payable                     (6,758)                 815
          Increase in accrued payroll
           and employee benefits              1,302                1,474
          Decrease in accrued rebates          (139)                (397)
          Decrease in restructuring
           reserve                             (711)                (775)
          Decrease in accrued interest         (101)                (281)
          Increase in other current
           liabilities                          392                1,374
          Net change in other assets
           and liabilities                   (9,618)                (194)
            Net cash provided by
             operating activities           100,290               77,564
  Cash flows from investing activities:
       Capital expenditures                 (19,365)             (14,037)
       Proceeds from sales of property,
        plant, and equipment                    992                  333
       Net payments for businesses
        acquired                            (69,882)              (6,702)
       Payments for intangibles              (1,223)                (960)
            Net cash used in investing
             activities                     (89,478)             (21,366)
  Cash flows from financing activities:
       Proceeds from credit facility        172,500              135,000
       Principal payments on credit
        facility                           (180,901)            (185,715)
       Proceeds from long-term debt              --                2,614
       Principal payments on long-term
        debt                                   (416)              (9,366)
       Proceeds from exercise of stock
        options                              15,187               12,972
       Proceeds received from employee
        stock purchase plan                   1,661                1,172
           Net cash provided by (used
            in) financing activities          8,031              (43,323)
  Effect of exchange rate changes on
   cash and cash equivalents                   (873)               4,859
  Net increase in cash and cash
   equivalents                               17,970               17,734
  Cash and cash equivalents at
   beginning of year                         40,602               22,868
  Cash and cash equivalents at end of
   year                                     $58,572              $40,602



              SYBRON DENTAL SPECIALTIES, INC. AND SUBSIDIARIES
                           ADDITIONAL DISCLOSURES
                    For periods ended September 30, 2005

  INTERNAL GROWTH:
                                    Professional  Specialty     Total
                                       Dental      Products      SDS
  Quarter                               12.9%       10.6%       11.8%

  Year to date                           6.3%       10.0%        8.0%

                                             Total SDS
                                       Foreign     Domestic
  Quarter                                12.1%      11.6%

  Year to date                           5.3%       10.3%



       DOMESTIC AND INTERNATIONAL SALES BY SEGMENT (In Thousands):

                                        Professional  Specialty     Total
                                            Dental     Products      SDS
  Quarter
    Domestic                               $54,958     $41,503     $96,461
    International                           36,307      37,628      73,935
      Total quarter sales                  $91,265     $79,131    $170,396

  Year to date
    Domestic                              $196,690    $152,264    $348,954
    International                          144,928     155,784     300,712
      Total year to date sales            $341,618    $308,048    $649,666



  Reconciliation of Fourth Quarter 2005 and Fiscal Year 2005 Pro Forma and
                                GAAP Results
                   (in millions, except per share amounts)
                                 (Unaudited)

                                            Q4 2005           FY 2005
  Net income, according to GAAP               21.5              76.7

  Less: stock compensation expense             3.1               7.5

  Plus: tax effect of including stock
   compensation expense                        0.5               2.0

  Pro forma net income                        19.0              71.2

  Fully diluted earnings per share
   according to GAAP                          0.52              1.85

  Tax-effected impact of pro-forma
   stock compensation                         0.06              0.13

  Pro forma fully diluted earnings per
   share                                      0.46              1.72

  Shares used in computing fully
   diluted earnings per share                 41.7              41.5



  Reconciliation of Estimated First Quarter 2006 and Estimated Fiscal Year
                       2006 Pro Forma and GAAP Results
                   (in millions, except per share amounts)
                                 (Unaudited)

                                            Q1 2006           FY 2006
                                          Low     High      Low     High
  Revenue                                160.0    165.0    685.0    705.0

  Pro forma net income                    16.2     18.1     81.9     88.2

  Less: stock compensation expense         2.5      2.5     11.3     11.3

  Plus: tax effect of including stock
   compensation expense                    0.8      0.8      3.7      3.7

  Net income, according to GAAP           14.5     16.4     74.3     80.6


  Pro forma fully diluted earnings per
   share                                  0.39     0.44     1.95     2.10

  Tax-effected impact of pro-forma
   stock compensation                     0.04     0.04     0.18     0.18

  Fully diluted earnings per share
   according to GAAP                      0.35     0.40     1.77     1.92

  Shares used in computing fully
   diluted earnings per share             41.3     41.3     42.0     42.0

  Stock compensation expense indicated in the reconciliation table is based
  on the Company's current expectations.  The actual expense may differ
  materially from the Company's estimate due to changes in the number of
  options granted or in the number of options forfeited.  See the section of
  this Press Release entitled CAUTION REGARDING FORWARD-LOOKING STATEMENTS
  for a discussion of risks and uncertainties which may cause the Company's
  actual stock compensation expense, as well as all other actual results, to
  differ materially from the estimates provided above.


http://www.newscom.com/cgi-bin/prnh/20001204/SDSLOGO

http://photoarchive.ap.org/

DATASOURCE: Sybron Dental Specialties, Inc.



CONTACT:  Bernard J. Pitz, Chief Financial Officer of Sybron Dental

Specialties, Inc., [phone]



Web site:  http://www.sybrondental.com/investors/index.html 

Web site:  http://www.sybrondental.com/ 

Copyright